Decoding RaymondsIndex: Deterioration Risk Is a Question About Clocks, Not Companies

On 14 August 2026, Korea's semi-annual reporting deadline closed. What surfaced afterward was not a new set of failing companies. It was a new set of observed ones.

Ten bio and healthcare issuers received a disclaimer of opinion on their half-year statements — among them Kainos Medicine, Cellumed, Syntekabio, Enzychem Lifesciences, Rolling Stone, Eutilex, Celestra, EOFlow, Olipass and Korea Union Pharm (Edaily Pharm, 22 Aug 2026). On the main board, eleven KOSPI issuers filed non-clean half-year opinions and seventeen KOSDAQ issuers missed the deadline entirely (Ajunews, 19 Aug 2026).

The number that matters for methodology is smaller: four. Kainos Medicine, Celestra, EOFlow and Olipass recorded negative total equity at the half-year mark — and under an amended listing rule, half-year negative equity became a listing-eligibility review trigger for the first time, applied to H1 2026 reports.

Read that carefully. The companies did not deteriorate in August. Their equity had been negative on 30 June. Under the previous rule, that fact would have entered the official record at the year-end audit — as much as six months later. The amendment did not change a single balance sheet. It moved a measurement point.

The concept: fragility is continuous, observation is discrete

Deterioration risk in the RaymondsIndex framework is often mistaken for a distress score — a number that says "this company is weak." It is not built to answer that. It is built to answer a harder question: how long can a company be weak before anyone is required to look?

A company's condition exists every day. Its recorded condition exists on a handful of dates chosen by rule. Between those dates lies an interval in which the condition can be arbitrarily bad and still be, formally, unrecorded. The length of that interval is not a property of the firm. It is a property of the measurement design — which is precisely why a regulator can halve it by decree, and did.

Korea parallel

This is the design premise behind the RaymondsIndex work on 3,109 Korean listed companies, where the leading-indicator ranking showed 85.9% concordance with the outcome ordering. That figure is routinely over-read, so the derivation matters: concordance is an order-agreement rate. It says the ranking put companies in broadly the right sequence. It is not a magnitude, and it is not an accuracy rate — it does not claim 85.9% of predictions were correct, and it does not claim anything about how far apart the ranked companies sit. What it supports is narrow and specific: that ordering information is available before the reporting calendar publishes it. This month's amendment is a regulator arriving at the same conclusion through a different door.

Academic frame

Beaver (1966, Journal of Accounting Research) showed that financial ratios of failing firms diverge from healthy ones several years before failure — the signal exists long before the filing that reveals it. Altman (1968, Journal of Finance) then demonstrated that combining ratios discriminates failure better than any single one. Neither result says a company fails suddenly. Both say the record of failure arrives suddenly, because the record is sampled.

For the individual investor

The practical translation is not "avoid weak companies." It is: know when you become entitled to know. Before you size a position, ask on what date the issuer is next obliged to publish something that could change your view — and how many months of unrecorded condition sit between now and then. That gap is knowable in advance. The event inside it is not.

General observations from public filings. Not investment advice.

#RaymondsRisk #RelationalRisk #CorporateGovernance #ReportingFrequency #GoingConcern #KOSDAQ